Results showed that the volume of xenograft gliomas were dramatically reduced in NFAT5(-) group, SBF2-AS1(-) group, and NFAT5(-)+SBF2-AS1(-) group compared with NFAT5(-)NC+SBF2-AS1(-)NC group. The gene discussed is SBF2; the disease is central nervous system cancer.